PHILADELPHIA, Sept. 9 /PRNewswire-FirstCall/ -- Ellen Strahlman, M.D.,
M.H.Sc., has been appointed Chief Medical Officer (CMO) at GlaxoSmithKline
(NYSE: GSK).
Ellen joins GSK from Pfizer Inc. where she was Vice President,
Licensing, Worldwide Business Development. During her career, Ellen has
worked in a variety of roles including Chief Executive Officer of Virogen
Limited, a biotechnology company; Chief Medical Officer and Global Head of
R&D for Bausch & Lomb, a pharmaceutical company; and as a senior medical
officer for the US government at the National Eye Institute at the National
Institutes of Health. She also has worked in leadership roles at Merck and
Novartis.
An ophthalmologist, Ellen was appointed this year as the industry
representative to the Food and Drug Administration/Center for Drug
Evaluation and Research (CDER) Dermatologic & Ophthalmic Drug Advisory
Committee. She also serves on the Columbia University Medical & Science
Technology Council and the Board of the Foundation of the American Academy
of Ophthalmology.
She has a Bachelor of Arts degree in biochemistry and mathematics from
Harvard University. She earned her medical degree at the Johns Hopkins
University School of Medicine, where she completed her internship in
general surgery and residency in ophthalmology. She also has a Master of
Heath Sciences' degree in epidemiology and statistics from the Bloomberg
School of Public Health at Johns Hopkins.
The Chief Medical Officer is the most senior physician leader of the
company with primary responsibility for matters of patient safety, general
medical governance, ethics and integrity, medical information, and
investigation involving human subjects relating to any GSK products
(pharmaceutical, biologicals and consumer healthcare medicinal products) in
development or on the market.
"This role unquestionably represents one of the most important
physician leadership opportunities within the global biopharmaceutical
industry," said GSK R&D Chairman Moncef Slaoui. "The depth of Ellen's
medical expertise, her general management and business development
experience and proven leadership skills make her ideally suited to take on
the challenges of this critical role."
GlaxoSmithKline -- one of the world's leading research-based
pharmaceutical and healthcare companies -- is committed to improving the
quality of human life by enabling people to do more, feel better and live
longer.
SOURCE GlaxoSmithKline
 back to top
Related links:
http://www.gsk.com
http://www.prnewswire.com/comp/801350.html/
CONTACT:
UK Media enquiries: Louise Dunn, Philip
Thomson, Claire Brough, Alice Hunt, or Gwenan White,
+020-8047-5502; US Media enquiries: Melinda Stubbee, Nancy
Pekarek or Mary Anne Rhyne, +1-919-483-2839, or Sarah Alspach,
+1-215-751-7709; European Analyst-Investor enquiries: David
Mawdsley, +020-8047-5564, Sally Ferguson, +020-8047-5543, Gary
Davies, +020-8047-5503; US Analyst-Investor enquiries: Frank
Murdolo, +1-215-751-7002, or Tom Curry, +1-215-751-5419, all of
GlaxoSmithKline
|
